TB Alliance and Mylan announce collaboration to commercialize pretomanid to treat tuberculosis (TB)

(Burness) Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. (NASDAQ: MYL), today announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

from EurekAlert! - Social and Behavioral Science http://bit.ly/2IGg4ot